Back

Safety and immunogenicity of a quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with a quadrivalent meningococcal conjugate vaccine (Menactra): a study protocol of a randomized non-inferiority trial in Mali

Viviani, S.; Hu, R.; Sow, S. O.; Tapia, M. D.; Haidara, F. C.; Diallo, F.; Traore, Y.; Traore, A.; Kodio, M.; Shi, L.

2025-12-01 infectious diseases
10.1101/2025.11.28.25341186 medRxiv
Show abstract

A phase IV clinical trial is designed to compare the safety and immunogenicity of a quadrivalent meningococcal polysaccharide vaccine (Walvax MPV ACYW135) compared with a quadrivalent meningococcal conjugate vaccine (Sanofi Pasteur Menactra(R)) in children aged 2-10 years in Mali, a country within the meningitis belt, to demonstrate the benefit that might be brought by vaccinations with meningococcal polysaccharide vaccines. Eligible subjects will be randomized at a 1:1 ratio to receive either Walvax MPV ACYW135 or Sanofi Pasteur Menactra(R). All subjects will be followed up for solicited/unsolicited adverse events and any serious adverse events. Immunogenicity will be determined with the level (titer) of functional antibodies by serum bactericidal assay using baby rabbit complement (rSBA) with non-inferiority demonstrated. Clinical Trial RegistrationNCT04450498

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.